Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab in Moderate-to-Severe Plaque Psoriasis (Japan, Phase 3)
jRCT2080221907Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of ixekizumab in plaque psoriasis (4 arms), sponsored by Eli Lilly and Company. Started Aug 2012; status: completed.
02
Drugs
ixekizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on jRCT2080221907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221907.